Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PD-1 Deep Dive: Lung Cancer Market Braced For Change

Nov 06 2016

• By Emily Hayes

Related Content

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Oct 19 2016

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch

Oct 25 2016

AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS

Oct 27 2016

Bristol Still Rules Immuno-Oncology, But For How Long?

Oct 27 2016

Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer

Oct 10 2016

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

Oct 10 2016

Timeline: Expected Clinical Trial Readouts For PD-1 Competitors

Nov 03 2016

New Keytruda Approval Rekindles An Old Debate

Jan 04 2016

Additional Topics

Clinical Trials ImmunoOncology Commercial Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window